Cell And Gene Articles, App Notes, Case Studies, & White Papers
-
Enhanced Development Of Virus-Specific Hybridomas
3/10/2025
Double-stranded DNA viruses cause various human diseases, which complicates diagnosis due to antigen conservation. Explore a cell line that produces specific monoclonal antibodies to aid biotherapeutics development.
-
Streamline Your AAV Process With A Production Platform
10/6/2025
AAVs are reshaping gene therapy, but scaling production introduces complexity. Learn how upstream process optimization can improve yield, consistency, and speed to meet growing demands.
-
Rapid Walkaway Solution For Assessing Viability In Cancer Organoids
3/31/2025
Assess anti-cancer compounds' effects on organoid size and morphology with colorectal cancer organoids as well as discover automated imaging and viability assays to streamline drug screening and aid early identification.
-
Avoiding The Pitfalls: 5 Lessons For Cell Therapy Manufacturing Success
10/13/2026
Cell therapy programs often stall between clinical and commercial supply because of manufacturing readiness, not clinical performance. Five recurring pitfalls, from partner choice to automation, show where early planning matters.
-
Standardizing Cryopreservation For Cell Therapy Supply Chains
6/3/2025
Explore how a standardized cryopreservation process is transforming leukapheresis handling by reducing risk and improving quality across the cell therapy supply chain.
-
A Transient Cell Line To Produce rAAV With Low-Level hcDNA Encapsidation
1/15/2025
Discover the ability of a novel HEK293 suspension cell line for efficient and scalable rAAV production across various serotypes with low encapsidated host cell DNA levels.
-
Optimizing Clinical Development Success In Hematologic Malignancies
11/12/2026
From choosing the right endpoints to identifying eligible patients from a limited pool, see what it takes to move a new therapy for leukemia, lymphoma, or myeloma from early-stage studies to approval.
-
Streamline Your mAb Manufacturing With Strategic Development And CDMO Compatibility
6/4/2025
Though the journey to mAb development begins at lab scale, for clinical trials and commercial distribution, a production process must be streamlined and scalable to 2,000 L production and above.
-
Ex-Vivo T Cell Depletion In Allogeneic HSCT
7/28/2026
Explore a flexible cell depletion strategy that selectively removes targeted immune cell populations while preserving beneficial subsets, supporting tailored graft engineering approaches.
-
Manufacturing Readiness: Why Compliance Is Won Or Lost On The Floor
8/6/2026
Achieve continuous regulatory readiness by embedding ALCOA++ compliance directly into manufacturing workflows to eliminate paper-based documentation risks.